

INSTITUTIONAL PRESENTATION 2015









OUR MISSION

To promote access to health and quality of life with fairly priced treatments in a profitable operation that assures sustainable growth to the company and the sharing with our workforce and with society of values generated.

OUR VISION

To consolidate operations in Latin America and expand into key global markets seeking recognition of physicians and communities by the launch of new products and profitability that allows the company's sustainable growth.

VALUES

Ethics, commitment, diversity, sustainable development, taking risks, focus and nationality.







GROWTH THROUGH WORK



Brazil

GO BEYOND, ALWAYS

- Founded in 1972, Eurofarma is currently the 1st multinational pharmaceutical company in Brazil.
- We count on the largest medical advertising force in the country, with approximately 2 thousand representatives.
- We have over 500 presentations in line.
- Our sales reached R\$ 2.1 billion in 2014.
- We operate in the main pharmaceutical segments through Business Units: Medical Prescription, Generics, OTC, Hospital & Biddings, Oncology, Service to Third Parties and Veterinary.



Argentina Belize Bolivia Chile Colombia Costa Rica El Salvador Guatemala Honduras Nicaragua Panama Peru Dominican Republic

We cover 68.55% of the Latin American market Our goal is to reach 90% by 2015









Opening of the 1st Productive Block in Itapevi Complex

First patent filing by Eurofarma

EMEA (European Medicines Agency) Certification for injectable lines: Cephalosporins Entered global consortium for conducting clinical trials for novel drugs in the country

First international patent filing

Acquisition of Wyeth brands: Ampicilina, Benzetacil, Pet-Ve-Oral, Wycilin, Helmiben, Rehidrat

Beginning of export activities Institute

Eurofarma

Establishment of

Establishment of Innovation Center





Entered FMD Vaccine market (Inova Biotechnology)

Acquisition of Gautier (Uruguay), Volta/ Famindustria (Chile) and Segmenta (Brazil) Establishment of Advisory Council

Changed organization form to "S.A." (Corporation)

Establishment of Supera joint venture along with Cristália laboratory

Acquisition of site in Colombia

Establishment of Orygen Biotechnology (joint venture with Biolab)

Establishment of Supera RX (joint venture with MSD and Cristália) Establishment of Momenta

Acquisition of site in Peru and Guatemala

2010

2009

Launched 1st monoclonal

antibody CIMAher ®

Acquisition of Quesada Farmacêutica (Argentina)

2011

2012

2013


2014

Innovation partnership with Dong-A (South Korea)

Shareholding with Melinta Therapeutics (USA)



SHARE



0,1%

Highlight in important therapeutic classes:

Hormones Antibiotics CNS

.4%

2,7% _0,7%

-0,5%

Source: Internal Data



MEDICAL GENERICS VETERINARY **ONCOLOGY** HOSPITAL PRESCRIPTION Tâmisa® Losartan potassium Newmast **Zoledronic acid** Polymyxin contraceptive antihypertensive drug Antimicrobiano/ antimastítico bisphosphonate antibiotic G Piperacillin +Tazobactam Selene® Cilostazol Aminofort Docetaxel platelet aggregation inhibitor acne treatment estimulador hormonal natural taxano antibiotic Gimi Gimi

Pondera® antidepressant



Norethisterone contraceptive



Creolina® disinfectant



Calcium Folinate other therapies against anemia



Parenteral Solution



OUR OPERATIONS

k.



ITAPEVI UNIT

THE SITE

- Opened in 2007, it is our main production site
- Total area is 300 thousand m² and 85 thousand m² of constructed area
- 4 manufacturing blocks

PRODUCTION

- Concentrates 80% of our production
- 1.170 workersemployees
- Current occupation: 50%

INFRASTRUCTURE

- Distribution Center: 12 thousand square metersm² with 20 thousand pallet locations
- Energy substation
- Ecumenical Chapel
- Eurofarma's Historical Center





UNITS



INTERLAGOS – SP

Manufacturing site dedicated to the production of glass vials



CAMPO BELO | SP

Lyophilized Production (oncology)



RIBEIRÃO PRETO - SP

Bulk Parenteral solutions



FREGUESIA DO Ó - SP

Production of antibiotics, penicillins, cephalosporins and carbapenems



RIO DE JANEIRO | RJ


Production of Veterinary Products



GOAL

Reach 90% of Latin American market by 2015.

Currently we cover 68.55% of the Latin American market





UNITS



CHILE

Sales Force: 28 professionals Brands Promoted: 30 Presentations promoted: -Medical specialties visited: Ophthalmology, Cardiology, Dermatology, Pediatrics, General Clinics



URUGUAY

Sales Force: **30 professionals** Brands Promoted: **49** Presentations promoted: **75** Medical specialties visited: **General Clinics**, **Psychiatry, Cardiology, Neurology, Endocrinology, Otorhinolaryngology. Gastroenterology, Urology, Pediatrics, Gynecology obstetrics**



ARGENTINA

Sales Force: **43 professionals** Brands Promoted: **24** Presentations promoted: **52** Medical specialties visited: **General Clinics, Cardiology, Gastroenterology**



BOLIVIA

Sales Force: 22 professionals Brands Promoted: 23 Presentations promoted: 75 Medical specialties visited: Psychiatry, Neurology, Otorhinolaryngology, Surgery, Gastroenterology, Urology, Cardiology, Rheumatology

OPERATIONS IN LATIN AMERICA



UNITS



PERU

Sales Force: **58 professionals** Brands Promoted: **62** Presentations promoted: **94** Medical specialties visited: **Cardiology**, **Dermatology**, **Gynecology obstetrics**, **Surgery**, **Neurology**, **Otorhinolaryngology**, **Urology**, **Gastroenterology**, **Ophthalmology**



COLOMBIA

Acquisition done in Sales Force: **32 profesionales** Presentations promoted: Medical specialties visited:



CENTRAL AMERICA

Acquisition done in 2013 **Headquarters located in Guatemala** Sales force: **95 professionals** Operations in Panama, Nicaragua, Honduras, El Salvador, Costa Rica, Dominican Republic

OUR PRODUCTIVITY









biotecnologia

EUROFARMA BIOLAB

Alliance between the two pharmaceutical laboratories to develop and produce 7 high cost biosimilar products to serve Brazilian government. EUROFARMA HERTAPE CALIER

Partnership with the Spanish-Brazilian company for the production of FMD (Foot and Mouth Disease) Vaccines SUPERA

EUROFARMA MSD CRISTÁLIA

Partnership responsible for the promotion, distribution and marketing of Medical Prescription products.



MOMENTA FARMACÊUTICA

Company focused in Medical Prescription products for Psychiatry, Gynecology, Respiratory System, among other specialties.

Momenta Farmacêutica is also responsible for manufacturing antibiotics such as Penicillin, Cephalosporin and Carbapenems, in different pharmaceutical presentations for human and veterinary use.

OUR PARTNERSHIPS





- ACHÉ
- ACTAVIS
- ALBITECH / GSN
- ALMIRALL
- ALTHAIA
- AMW
- BIODERMA
- CHEMO
- CIMAB
- DANISCO (DUPONT)
- DONG-A
- DSM
- HYPERMARCAS
- JUBILANT
- KERN
- LUPIN
- MELINTA
- MERIAL
- NEURIM
- NIPRO
- NOVO NORDISK
- ORDESA
- PHARMA MEDICO
- PHASILAB
- RANBAXY
- RECOMBIO
- SMB
- SOFTCAPS



LICENSED PRODUCTS REPRESENT AROUND 10% OF OUR INCOME

HOW WE ACT



ADVISORY COUNCIL

Established in 2011 with the objective of supporting and evaluating **company's strategic decisions**.

ETHICS COUNCIL

Responsible for the evaluation of the **corporate's ethical behavior** (actions, media, relations with concerned public, etc.).

COMPLIANCE AND RISK MANAGEMENT

Responsible for monitoring **company's behavior and actions, so that best practices are always executed** and that they are in accordance with national regulations and with our internal conduct code.





INDEPENDENT OMBUDSMAN CHANNEL

Direct and confidential **internal communication** channel, which can be used by any employee or service provider to expose situations that present any behavior deviation.

INVESTMENTS COMMITTEE

It meets periodically to discuss **investment opportunities**, taking into consideration the operational risk, financial investment analysis and company strategy.

SUSTAINABILITY

A committee periodically discusses **corporate responsibility actions, which encompass social and environmental programs**. The objective is to ensure the sustainable development of our business and society and to preserve the environment.





INVESTMENTS IN RESEARCH, DEVELOPMENT AND INNOVATION* ACCOUNT FOR 6% OF OUR NET SALES

Our forecast is that this rate reaches

12% in 2020

Pipeline: **176** projects





* Root Projects, incremental projects and pharmacotechnical development.






MARKET SHARE

by type of company (US\$ list price)

Local companies grew faster since their portfolios fit the profile of market evolution.



● Local ● Regional ● Others



MARKET SHARE

Total (Retail x Non-retail): US\$ 26 billion US\$ considering discounts in 2014

68,4% • Retail Market (Varejo)

31,6% • Non-Retail Market (Não Varejo)

Definitions

Drug Stores (retail) US\$ 17.8 billion

Institutions, Hospitals, Clinics, and Government (non-retail) US\$ 8.2 billion


\$ 17,8 \$ 8,2

Source: IMS Health Dec/14 - PMB. Non retail Dollar exchange rate US\$ 1 = R\$ 2,34



EVOLUTION

Turnover and ranking (IMS/PMB)




Employees

2014 5.900 2013 5.798 2012 5.235 2011 4.886 2010 4.137 2009 3.397 2008 3.289 2007 2.701 2006 2.900 2000 1.130

Source: PMB PPP Dec/ 14 IMS - Brasil * It does not consider Momenta's and Supera's product portfolios.




Ranking 2013






PRESCRIPTION EVOLUTION 2014

- Eurofarma
- Ranking Position





OPERATIONAL STRUCTURE




Gross Margin (%): (Gross Profit – Indirect Oc)./ Net Sales Operational Structure (%): (Operational Costas + AG – P&D) / Net Sales

Source: Eurofarma Management Report - Dec/14



LIQUIDITY INDICATOR




Current Liquidity - (Current assets/current liabilities) Current dry Liquidity - (Current assets-stock) / current liabilities

Source: Eurofarma Management Report - Dec/14



EBITDA

Generation of Cash Flow (in million R\$)





EBITDA - Net earnings before interests, tax, depreciation/amortization. Value generation - EBITDA/ Net Sales

Source: Eurofarma Management Report - Dec/14

OUR ACTIONS



ENVIRONMENTAL MANAGEMENT SYSTEM (EMS)

MAIN PROJECTS

- Wastewater treatment stations
- Monitoring of indicators: water, energy, hazardous residues
- Greenhouse gases Fleet
- Renewable energy
- Water reuse
- Correct disposal of drugs
- · Selective waste collection



ISO 14001 Certification - Environmental Management System





PROGRAMS

- Eurofarma Nursing Center
- Educate to Recycle
- Raw materials
- Second Generation Raw material
- Conect@
- Eurofarma School-Workshop
- Administrative Techniques
- Office Assistant







WE SPONSOR CULTURAL AND SPORTS PROJECTS WITH THE OBJECTIVE OF CONTRIBUTING TO THE GROWTH AND STRENGTHENING OF NATIONAL ARTS



CULTURE

R\$ 2.7 million

invested in culture in 2014.

In 2014, **8 projects**

received allocations through Rouanet and Proac Laws.

SPORTS

R\$ 1.5 million

invested in 2014 through incentive laws.

R\$ 8.1 million

invested in sports through our own resources.

In 2014, 10 projects received allocations and over 2.3 thousand children and young people were directly benefited by resources from federal and state sports regulations (PIE).



GPTW (2014)

3rd place in pharmaceutical industry category in Brazil.

EXAME GUIDE (FROM 2003 TO 2013)

Present in the guide that lists the best companies to work with in Brazil.

EXAME SUSTAINABILITY GUIDE (2013)

Most Sustainable company in the Pharmaceutical segment.

TOP HOSPITAL AWARD (2013)

Evaluates and recognizes services performed by suppliers of the medical and hospital sectors.

BUMERANGUE CORPORATE TRAINING AWARD (2013)

Granted by Sindusfarma to companies with the best training, development, recruiting and selection programs of pharmaceutical industry Human Resources.

1000 BEST FROM DINHEIRO (2014)

One of the best companies from the segment regarding Social responsibility, Human Resources Management and Corporate Governance.

ÉPOCA NEGÓCIOS 360 MAGAZINE (2014)

Champion in the pharmaceutical sector among 250 best companies from the sector.



IN 2014 WE MIGRATED TO GPTW



GREAT PLACE TO WORK		2005	2006	2007	2008	2009	2010	2011	2012	2013
Presence among top 150 companies	16	Ú	7 th	Ú	16	5 th	8 th	7 th	16	16
1st place in best pharmaceutical company category					16		16	16	16	
Yearly special Category			9th Best company for women		1st Best in Health Quality of Life				1st Prácticas de remuneración	
Pharmaceutical, hygiene, and cleaning companies	MSD, Novartis, Pfizer, Schering, Plough, Boehringer Ingelheim, Medley, Sankio e Novo Nordisk	Bristol Myers, Boeringer Ingelheim, Astrazeneca, Lily, Novartis, Schering- Plough, Novo Nordisk, Sankio e Aspen	Janssen-Cilag, Medley, Sanofi Aventis, Schering- Plough, Aspen e Sankio	Janssen-Cilag, Medley, Mantecorp e Novo Nordisk	Sanofi Aventis, Wyeth, Genzyme e Novo Nordisk	Sanofi Aventis, Wyeth, Genzymwe e Novo Nordisk	Sanofi Aventis, Colgate, Palmolive, Nive, Genzyme, Phito Fórmulas e Novo Nordisk	Colgate, Palmolive, Genzyme, GlaxoSmithKli ne, Boticário, Nycomed, Ourofino Agronegócio, P&G, Sanofi Aventis e Zambon	GlaxoSmithKli ne, Novo Nordisk, Ourofino Agronegócio, Phyto Fórmulas, Takeda e Zambon	Ourofino Agronegócio, Takeda e Zambon

